SG Americas Securities LLC Has $1.91 Million Stock Position in Adaptive Biotechnologies Corporation $ADPT

SG Americas Securities LLC increased its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 37.8% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 137,758 shares of the company’s stock after purchasing an additional 37,823 shares during the period. SG Americas Securities LLC’s holdings in Adaptive Biotechnologies were worth $1,912,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Ameriprise Financial Inc. raised its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $65,942,000. Geode Capital Management LLC increased its holdings in shares of Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after acquiring an additional 110,825 shares during the last quarter. Finally, State Street Corp raised its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. The trade was a 41.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 5,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $19.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 411,775 shares of the company’s stock, valued at $7,823,725. This represents a 1.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 698,316 shares of company stock valued at $11,655,488 in the last 90 days. 5.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ADPT has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. JPMorgan Chase & Co. dropped their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. TD Cowen raised their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday. Finally, Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average price target of $20.50.

Adaptive Biotechnologies Trading Down 5.3%

NASDAQ:ADPT opened at $21.19 on Friday. The stock has a 50 day simple moving average of $15.95 and a 200 day simple moving average of $15.83. The stock has a market cap of $3.39 billion, a P/E ratio of -64.21 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 1-year low of $9.96 and a 1-year high of $22.80.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.20) EPS. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.